Ludwig Institute for Cancer Research Limited

Licentia, Ltd.

Seppo Ylā-Herttuala

Kari Alitalo

Carl-Henrik Heldin

Arne Östman

Olli Leppänen

The invention relates to a combination of (a) an inhibitor of platelet-derived growth factor (PDGF) activity and (b) a vector for vascular endothelial growth factor (VEGF-, especially VEGF-C) gene transfer, a pharmaceutical preparation comprising (a) and (b) in combination together with a pharmaceutically acceptable carrier material; a product comprising (a) and (b) as defined above and optionally a pharmaceutically acceptable carrier material, for simultaneous, chronologically staggered or separate use; a method of administering or the use of said combination or product for the treatment of endothelial damage; and/or to the use of (a) and (b) for the manufacture of said pharmaceutical preparation or product for the treatment of endothelial damage.

Growing community of inventors

Vuirela, Finland

Seppo Ylā-Herttuala